

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GREGORY RAYMOND BEBERNITZ

APPLICATION NO: 10/529,670

FILED: MARCH 29, 2005

FOR: SUBSTITUTED (THIAZOL-2-YL)-AMIDES OR SULFONAMIDES AS
GLUCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF
TYPE 2 DIABETES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statements filed December 12, 2005, and January 30, 2006. Please charge Deposit Account No. 50-4409 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Ave. 232J
Cambridge, MA 02139

(617) 871-4125

Date: January 22, 2009



Mark Milstead
Attorney for Applicants
Reg. No. 45,825